https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer?utm_medium=email&utm_source=govdelivery
On April 8, 2025, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and...
fdanivolumabipilimumabunresectablemetastatic
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipilimumab?redirect=true
Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes...
definitionipilimumabncidrugdictionary
https://www.cancer.gov/types/skin/research/pembrolizumab-ipilimumab-resistance
KEYNOTE-002 was designed to test the safety and efficacy of two doses of pembrolizumab compared with chemotherapy in patients with ipilimumab-resistant...
pembrolizumabipilimumabresistantmelanomanci
https://www.ncbi.nlm.nih.gov/Structure/pdb/6RP8
Antibody Ipilimumab heavy chainAntibody Ipilimumab light chainCytotoxic T-lymphocyte protein 4
crystal structureipilimumabfab
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer
On April 8, 2025, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and...
fdanivolumabipilimumabunresectablemetastatic
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2014-02674
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
phase iiiiitrialnivolumabipilimumab